Diving Beyond the Surface: Ethical Frontiers of Fecal Microbiota Transplantation in the Pediatric Population

Vol. 30, Issue 4 (December 2025)

Roxana-Mihaela Bratu, MD
Pediatric Gastroenterology Department,
Sf. Maria County Clinical Emergency Children's Hospital
Iasi, Romania

 

Laura-Mihaela Trandafir, MD, PhD
Professor, "Grigore T. Popa" University of Medicine and Pharmacy
Pediatric Gastroenterology Department,
Sf. Maria County Clinical Emergency Children's Hospital
Iasi, Romania
 

Anca-Victorița Trifan, MD, PhD
Professor, "Grigore T. Popa" University of Medicine and Pharmacy
Institute of Gastroenterology and Hepatology,
Sf. Spiridon County Clinical Emergency Hospital
Iasi, Romania
 

Georgiana-Emmanuela Gîlcă-Blanariu, MD, PhD
Lecturer, "Grigore T. Popa" University of Medicine and Pharmacy
Institute of Gastroenterology and Hepatology,
Sf. Spiridon County Clinical Emergency Hospital
Iasi, Romania
 

1. Introduction

Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic strategy for a variety of gastrointestinal and non-gastrointestinal disorders in both adult and pediatric populations. Its efficacy has been most clearly demonstrated in the treatment of recurrent Clostridioides difficile infection (rCDI), for which it is currently included in international clinical guidelines.^{1, 2}

Although growing evidence supports the potential utility of FMT in various disorders, including metabolic, neurological, and inflammatory diseases, formal recommendations, particularly in pediatrics, remain limited.³ The European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) have jointly endorsed the use of FMT in children only under specific clinical scenarios:¹

• Recurrent CDI, defined as recurrence of symptoms within eight weeks of completing treatment, in either of the following circumstances:
  • ≥3 episodes of mild-to-moderate CDI with failure of a prolonged vancomycin taper (6–8 weeks), with or without adjunctive therapies (e.g., rifaximin, nitazoxanide)
  • ≥2 episodes of severe CDI requiring hospitalization and associated with substantial morbidity
• Moderate CDI unresponsive to standard therapies for at least a week (including vancomycin)
• Severe or fulminant CDI, including C. difficile colitis, with no clinical response to standard antimicrobial therapy after 48 hours

Despite increasing interest, data on the safety, efficacy, and long-term outcomes of FMT in children remain sparse.⁴ This knowledge gap is particularly concerning given the evolving nature of the pediatric gut microbiome, which is closely linked to immunologic, metabolic, and neurologic development.⁵

2. Current Challenges in Pediatric FMT

While preliminary evidence suggests that FMT may be effective in pediatric populations, several clinical and logistical challenges continue to hinder its widespread implementation:⁶

• Mircobiome variability
  • The pediatric gut microbiome is both dynamic and less resilient than that of adults. This developmental immaturity complicates donor-recipient compatibility, with potentially unpredictable long-term effects on immune and metabolic programming.⁷
• Route of administration
  • Multiple administration routes are available, including oral capsules, nasogastric or nasojejunal tubes, enemas, and colonoscopies. Each approach entails specific risks, tolerability concerns, and efficacy profiles, with no current consensus on an optimal route in pediatric populations.⁴
• Lack of standardized guidelines
  • The absence of unified, evidence-based clinical protocols for pediatric FMT results in wide interinstitutional variability, making standardized care and outcome comparison difficult.⁸

3. Safety and Risk Procedure

FMT is generally well tolerated in pediatric populations. Common adverse events include mild gastrointestinal and general symptoms (transient bloating, abdominal pain, diarrhea, nausea, constipation, and low-grade fever), which are usually self-limiting. However, potential procedural risks, particularly those associated with sedation and endoscopic delivery, must be discussed with families during pretreatment counseling.⁸

Serious complications, though rare, have been reported, including aspiration pneumonia with upper GI delivery and exacerbation of inflammatory bowel disease, occasionally necessitating hospitalization. To date, no fatalities linked directly to FMT have been documented in pediatric patients.⁹

Although emerging data indicate that FMT is tolerated even in immunocompromised children, the risk of disease flares in patients with immune-mediated conditions such as IBD warrants close monitoring.¹⁰

Long-term safety remains uncertain as early alterations to the gut ecosystem have been associated with the development of autoimmune, metabolic, and neuropsychiatric disorders. As such, longitudinal follow-up extending beyond current norms (often less than a few years) is essential; however, maintaining robust datasets remains challenging, as many patients fail to return for reevaluation or gradually lose compliance with follow-up protocols.¹¹

4. Informed Consent

Informed consent for pediatric FMT must be both comprehensive and ethically grounded. Discussions should clearly outline known risks, uncertain long-term consequences, and potential for pathogen transmission. Consent should involve legal guardians and, where appropriate, the child’s assent, aligning with principles of shared decision-making and family-centered care.¹²

5. Donor Selection

Donor screening is a critical component of FMT, particularly in pediatric practice, where the recipient microbiome is not yet stable. Donor candidates must undergo rigorous screening, including detailed health histories and comprehensive microbiological testing of both blood and stool, in accordance with prevailing clinical guidelines.¹³

Recent safety alerts from the U.S. Food and Drug Administration (FDA) regarding the risk of transmitting multidrug-resistant organisms underscore the importance of vigilance in donor screening.¹⁴

While most pediatric FMTs utilize adult donors, this approach raises theoretical concerns. Introducing an adult microbiome into a developing gut may perturb immune or metabolic homeostasis and has been hypothesized to contribute to adverse outcomes such as rapid weight gain and early immune senescence.¹⁵ Age-matched pediatric donors may provide a more physiologically compatible alternative. However, such practices are still underexplored, and additional research is necessary to determine their safety, practicality, and efficacy. Standardized guidelines for pediatric donor criteria and stool preparation are needed.

6. Research Gaps and Regulatory Considerations

Despite its therapeutic promise, FMT in pediatric populations remains hampered by a lack of robust clinical evidence and regulatory clarity. Key challenges include:¹⁶

• absence of large, randomized, controlled trials
• inconsistent follow-up durations
• heterogeneous delivery techniques and donor protocols
• ambiguity in global regulatory frameworks

Globally, there is no harmonized legal definition or regulatory framework for FMT. The heterogeneity of donor material further complicates regulatory classification. The FDA originally defined stool-derived microbiota as both a drug and a biological product, thereby mandating an Investigational New Drug (IND) application for its clinical use. This led to accessibility issues and a rise in unsupervised, potentially unsafe practices. As a compromise, the FDA now exercises enforcement discretion in cases of rCDI unresponsive to standard treatments.¹⁷

Consensus statements have emphasized the importance of regulating stool banks and establishing national-level oversight. However, significant gaps remain in defining best practices, particularly for pediatric applications.¹³

7. Conclusion

FMT represents a promising intervention for rCDI in children, with early data supporting its short-term safety and efficacy. However, its broader use in pediatrics remains limited by the lack of sufficient long-term data, regulatory fragmentation, and ethical considerations.

Future progress in pediatric FMT will depend on integrating personalized approaches such as immunological, metagenomic, and metabolomic matching to enhance both safety and therapeutic precision. However, its broader clinical adoption must be grounded in rigorous multicenter trials, long-term outcome data, and age-appropriate donor strategies. Until such evidence and regulatory consensus emerge, FMT in children should be approached with caution, guided by individualized clinical assessment and shared decision-making.

References

1. Davidovics, ZH, S. Michail, M. Nicholson, L. Kociolek, N. Pai, R. Hansen, T. Schwerd, A. Maspons, R. Shamir, H. Szajewska, N. Thapar, T. de Meij, A. Mosca, Y. Vandenplas, S. Kahn and R. Kellermayer, "Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for," J Pediatr Gastroenterol Nutr., vol. 68, no. 1, pp. 130-143, 2019.
2. A. Peery, C. Kelly, D. Kao, B. Vaughn, B. Lebwohl, S. Singh, A. Imdad, and O. Altayar, "AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases," Gastroenterology, vol. 166, no. 3, pp. 409-434, 2024.
3. D. Yi, T. Li, Y. Xiao, X. Zhang, Q. Hao, F. Zhang, T. Qiu, G. Yang, X. Sun, Y. Dong and N. Wang, "Fecal microbiota transplantation for the treatment of intestinal and extra-intestinal diseases: Mechanism basis, clinical application, and potential prospect," Bioeng Transl Med., vol. 10, no. 2, p. e10728, 2024.
4. C. Chen and C. Chiu, "Current and future applications of fecal microbiota transplantation for children," Biomed J., vol. 45, no. 1, pp. 11-18, 2022.
5. V. Ronan, R. Yeasin and E. Claud, "Childhood Development and the Microbiome-The Intestinal Microbiota in Maintenance of Health and Development of Disease During Childhood Development," Gastroenterology, vol. 160, no. 2, pp. 495-506, 2021.
6. E. Lauwers, J. Sabino, I. Hoffman and K. van Hoeve, "Faecal microbiota transplantation in children: A systematic review," Acta Paediatr., vol. 113, no. 9, pp. 1991-2002, 2024.
7. L. Putignani, F. Del Chierico, A. Petrucca, P. Vernocchi, and B. Dallapiccola, "The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood," Pediatr Res., vol. 76, no. 1, pp. 2-10, 2014.
8. X. Gu, Z. Chen, and S. Zhang, "Fecal microbiota transplantation in childhood: past, present, and future," World J Pediatr., vol. 19, no. 9, pp. 813-822, 2023.
9. J. Wang, Q. Liang, H. Dou, and Y. Ou, "The global incidence of adverse events associated with fecal microbiota transplantation in children over the past 20 years: A systematic review and meta-analysis." J Gastroenterol Hepatol., vol. 37, no. 11, pp. 2031-2038, 2022.
10. L. Zeng, Y. Deng, K. Yang, J. Chen, Q. He, and H. Chen, "Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis," Front Immunol., vol. 13, p. 944387, 2022.
11. A. Gulati, M. Nicholson, A. Khoruts, and S. Kahn, "Fecal Microbiota Transplantation Across the Lifespan: Balancing Efficacy, Safety, and Innovation," Am J Gastroenterol. , vol. 118, no. 3, pp. 435-439, 2023.
12. S. Metselaar and G. Widdershoven, "Ethical Issues in Fecal Microbiota Transplantation: Taking Into Account Identity and Family Relations," Am J Bioeth., vol. 17, no. 5, pp. 53-55, 2017.
13. G. Cammarota, G. Ianiro, C. Kelly, B. Mullish, J. Allegretti, Z. Kassam, L. Putignani, and M. Fischer, "International consensus conference on stool banking for faecal microbiota transplantation in clinical practice," Gut, vol. 68, no. 12, pp. 2111-2121, 2019.
14. United States of America - Food and Drug Administration, "Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms," [Online]. Available: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse-events-likely.
15. S. Hourigan and M. Oliva-Hemker, "Fecal microbiota transplantation in children: a brief review," Pediatr Res., vol. 80, no. 1, pp. 2-6, 2016.
16. B. Gurram and P. Sue, "Fecal microbiota transplantation in children: current concepts," Curr Opin Pediatr., vol. 31, no. 5, pp. 623-629, 2019.
17. Z. Grigoryan, M. Shen, S. Twardus, M. Beuttler, L. Chen and A. Bateman-House, "Fecal microbiota transplantation: Uses, questions, and ethics," Med Microecol. , vol. 6, p. 100027, 2020.